Saturday 17 October 2026
Export FBLG’s income statement to Excel — free account
FibroBiologics Inc.
FBLG Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.5% and free cash flow grew 21.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.95
0.05
−5.00%
Follow FBLG
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
Current Ratio |
3.61 | 1.12 | 1.00 | 0.37 | 0.27 |
Net Debt/EBITDA |
0.31 | 0.37 | 1.09 | 0.57 | 0.26 |
Debt/Assets |
0.00% | 55.75% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 3.35 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.88 | 1.07 | 0.34 | 0.79 | 0.89 |
Capex/Depreciation |
(0.31) | (0.32) | (0.96) | 0.00 | — |
Interest Coverage |
(81.61) | (686.85) | (60.47) | (6.83) | (394.50) |
| (419.44%) | (559.73%) | 1,389.57% | 193.76% | 0.00% | |
| (143.08%) | (78.97%) | (228.99%) | (193.54%) | 0.00% | |
ROIC |
(824.53%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(343.26%) | (479.84%) | (2,298.91%) | 115.13% | 122.64% |
Average Days of Receivables |
— | — | — | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(7.46) | (7.35) | (4.89) | (2.88) | 0.00 |
Cash per Share |
2.19 | 8.51 | 6.49 | 1.61 | 0.00 |
Shareholders Equity per Share |
2.76 | 1.66 | 0.89 | (2.83) | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.76 | 1.66 | 0.89 | (2.83) | 0.00 |
Free Cash Flow |
(16.66) | (12.08) | (6.90) | (4.07) | (1.41) |
Working Capital |
4.59 | 1.50 | 0.03 | (4.45) | (1.29) |
Capital Expenditures |
(0.26) | (0.18) | (0.49) | — | — |
Net Current Asset Value |
2.89 | 0.52 | (1.35) | (6.19) | (1.29) |
| Other line items | |||||
Quick Ratio |
2.78 | 1.10 | 1.00 | 0.36 | 0.23 |
Depreciation/Fixed assets |
0.99 | 0.70 | 0.65 | 0.00 | — |
Cash ROIC |
(150.73%) | (46.68%) | (66.21%) | 235.03% | 159.68% |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(7.34) | (7.24) | (4.53) | (2.88) | 0.00 |
Capex per Share |
(0.12) | (0.11) | (0.35) | 0.00 | — |
Average Payables |
1.82 | 2.07 | 1.10 | 0.50 | — |
Average Assets |
13.03 | 14.13 | 8.32 | 2.65 | — |
Average Common Equity |
4.45 | 1.99 | (1.37) | (2.64) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates